Filtered By:
Management: Marketing
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 564 results found since Jan 2013.
Top Companies in Genomics
From portable genome sequencers until genetic tests revealing distant relations with Thomas Jefferson, genomics represents a fascinatingly innovative area of healthcare. As the price of genome sequencing has been in free fall for years, the start-up scene is bursting from transformative power. Let’s look at some of the most amazing ventures in genomics!
The amazing journey of genome sequencing
Genome sequencing has been on an amazing scientific as well as economic journey for the last three decades. The Human Genome Project began in 1990 with the aim of mapping the whole structure of the human genome and sequencing it. ...
Source: The Medical Futurist - May 30, 2017 Category: Information Technology Authors: nora Tags: Genomics Personalized Medicine AI artificial intelligence bioinformatics cancer DNA dna testing DTC gc3 genetic disorders genetics genome sequencing personal genomics precision medicine Source Type: blogs
Big Data and the Social Good: The Value for Healthcare Organizations
The following is a guest blog post by Mike Serrano from NETSCOUT.
It’s a well-known fact that Facebook, Google, and our phone companies collect a lot of information about each of us. This has been the case for a long time, and more often than not it’s to improve the user experience of the services we rely on. If data is shared outside the organization, it’s anonymized to prevent the usage of any one individual from being identified. But it’s understandable while this practice has still sparked a passionate and longstanding debate about privacy and ‘big brother’-style snooping.
What is often forgotten, however,...
Source: EMR and HIPAA - May 22, 2017 Category: Information Technology Authors: Guest Blogger Tags: Healthcare HealthCare IT Population Health Management Mike Serrano NETSCOUT Public Health Subscriber Information Source Type: blogs
Scott Gottlieb And The Goldilocks Theory Of Bringing Change To The FDA
With the nomination of Dr. Scott Gottlieb to head the U.S. Food and Drug Administration (FDA) headed to the Senate floor, we can expect another Goldilocks debate. Like the heroine of the classic tale who famously tested the three bowls of porridge to find one too hot, one too cold, and one “just right,” participants will debate whether today’s FDA is too lenient, too tough, or just right in reviewing new prescription drugs.
That Dr. Gottlieb is qualified for the role he has been nominated for appears beyond question. What critics take issue with is whether his extensive experience ties him too closely to the entities...
Source: Health Affairs Blog - May 1, 2017 Category: Health Management Authors: Ian Spatz Tags: Costs and Spending Drugs and Medical Innovation Health Professionals Public Health 21st Century Cures Act Big Pharma FDA off-label drugs off-label promotion Source Type: blogs
A New Attempt Emerges To Bridge GOP Divisions On AHCA (Updated)
April 21 Update: New Aid For State Formulary Review At REGTAP
On April 17, 2017, CMS announced that it would be turning the job of drug formulary review for qualified health plans over to state regulators in the thirteen HealthCare.gov states that have plan management responsibility. On April 19, CMS offered at its REGTAP.info website (registration required) a seminar on the qualified health plan (QHP) application review tools for prescription drugs that the states may use for these reviews.
The EHB Category and Class Drug Count Tool, which is new for the 2018 QHP review period, reviews drug lists to ensure that QHPs com...
Source: Health Affairs Blog - April 20, 2017 Category: Health Management Authors: Timothy Jost Tags: Costs and Spending Featured Following the ACA Insurance and Coverage Source Type: blogs
The 5 Best Podcasts on Empowerment
You're reading The 5 Best Podcasts on Empowerment, originally posted on Pick the Brain | Motivation and Self Improvement. If you're enjoying this, please visit our site for more inspirational articles.
We often face decisions with anguish over whether it will be the right choice, because we are afraid of the unknown. We may fear that whatever happens will result in failure. This is where empowerment can make a difference in feeling that you do in fact have control over what is happening to you. To know that you make a decision that is the best for yourself creates a balance between responsibilities and wishes. Of course,...
Source: PickTheBrain | Motivation and Self Improvement - April 9, 2017 Category: Consumer Health News Authors: Larissa Gomes Tags: confidence featured self improvement best blogs on empowerment best podcasts on empowerment pickthebrain Source Type: blogs
Solutions That Will Be Essential for the Future of Healthcare
By ROBERTO ASCIANO
We are living in an age where thousands upon thousands of individuals and companies are trying to find faster, better and cheaper ways to get things done leveraging the latest digital technologies. We are so completely surrounded by efforts to innovate, disrupt and accelerate, that it may come as a surprise to find out that “innovation” has been around ever since our earliest ancestors shed their body hair and started walking upright.
Since those early days, our ancestors have sought solutions to their everyday problems and the “technology” they leveraged was whatever the environment around them...
Source: The Health Care Blog - April 3, 2017 Category: Consumer Health News Authors: Matthew Holt Tags: Health 2.0 Health 2.0 Europe Roberto Asciano Speaker Source Type: blogs
A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option
There are two different storms brewing in the pharmaceutical world. On the one hand there is increasing opposition to the very high prices of drugs. On the other hand there is ever more pressure to accelerate access to drugs for seriously ill patients. President Trump expressed both of these very different concerns in his January 31st meeting with pharmaceutical executives, during which he called drug prices “astronomical” while also vowing to “streamline” the process of drug approval. It is vital that the cost of new drugs not overwhelm patients and the health care system. It is also important to get drugs to desp...
Source: Health Affairs Blog - March 20, 2017 Category: Health Management Authors: Robert Bohrer Tags: Costs and Spending Drugs and Medical Innovation Drugs and Medical Technology accelerated approval conditional approval drug pricing Duchenne Muscular Dystrophy early access parallel track Source Type: blogs
The scary evolution of direct-to-consumer advertising
One night in 1997, as Americans watched Touched by an Angel they were touched by something else unexpected: an ad for a prescription allergy pill called Claritin, sold directly to patients.
Prescription drugs had never been sold directly to the public before — a marketing tactic called direct-to-consumer or DTC advertising. How could average people, who certainly had not been to medical school, know if the medication was appropriate or safe without a doctor’s recommendation?
Soon, ads for Meridia, Propecia, Singulair, Paxil, Prozac, Vioxx, Lipitor, and Viagra followed — exhorting patients to “ask their doct...
Source: Kevin, M.D. - Medical Weblog - March 17, 2017 Category: Journals (General) Authors: < a href="http://www.kevinmd.com/blog/post-author/martha-rosenberg" rel="tag" > Martha Rosenberg < /a > Tags: Conditions Cancer Source Type: blogs
Gluten and diabetes: The headlines get it wrong again
Another study was released recently that purports to “prove” that gluten-free diets are associated with increased risk for type 2 diabetes. As with many studies of this type, the findings were misinterpreted but fed into the media’s continual need for titillating headlines. I thought this hubbub would pass by now, but reports about this study (such as this piece of tripe from The Washington Post) seem to be gaining more traction than usual, fueling the misunderstanding and misinformation that plagues nutritional thinking. While I thought this would just pass, it looks like it will not and I’m theref...
Source: Wheat Belly Blog - March 14, 2017 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Lifestyle blood sugar diabetes gluten glycemic grains Inflammation Source Type: blogs
The Patient Expert: Healthcare ’s Untapped Workforce
By KYM MARTIN
One of my favorite patient advocates consultants–that’s Kym Martin (far right) on a panel I ran at Health 2.0–has a new job at one of the most interesting patient consultant companies. Here’s her story!–Matthew Holt
Let me ask you two questions.
On a scale of 1 to 10, how would you rate the quality of the “real-world” patient insights your team gathers to inform your mission-critical, life-altering work?
Are you clear on the needs, trends, and challenges facing the patients you’re trying to serve?
Why Listen to Me?
For the past four years, I’ve listened to hundreds of h...
Source: The Health Care Blog - March 9, 2017 Category: Consumer Health News Authors: Matthew Holt Tags: Patients Tech Kym Martin patient consultants WeGo Health Source Type: blogs
Hey, Machine Learning (If That ’ s Even Your Real Name)
By LEONARD D’AVOLIO
Hey Machine Learning,
I heard what Forbes said about your “setback” at MD Anderson. I also heard rumors going around HIMSS that maybe it’s “too soon” for you to be in healthcare. At first I thought, “serves you right.” There was so much hype that I could barely recognize you.
Then I realized that, in a way, we’re all to blame. The journalists, vendors, researchers, and data scientists – all of us that tried to make you popular in healthcare. I guess things just sort of got out of hand.
You have to believe me when I say we meant well. We wanted people to see how special y...
Source: The Health Care Blog - March 7, 2017 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs
Hey, Machine Learning
By LEONARD D’AVOLIO
Hey Machine Learning,
I heard what Forbes said about your “setback” at MD Anderson. I also heard rumors going around HIMSS that maybe it’s “too soon” for you to be in healthcare. At first I thought, “serves you right.” There was so much hype that I could barely recognize you.
Then I realized that, in a way, we’re all to blame. The journalists, vendors, researchers, and data scientists – all of us that tried to make you popular in healthcare. I guess things just sort of got out of hand.
You have to believe me when I say we meant well. We wanted people to see how special y...
Source: The Health Care Blog - March 7, 2017 Category: Consumer Health News Authors: John Irvine Tags: Tech Uncategorized Source Type: blogs
Chimeric Antigen Receptor Cancer Immunotherapies Continue to Look Promising
Cancer treatments based on the use of chimeric antigen receptors are one of the more promising of present forms of immunotherapy. In trials they are producing good results in patients with late stage leukemia and lymphoma, who lack any other options, and are comparatively fragile and beaten down by the combination of disease and prior aggressive treatments. They should do even better once deployed earlier, for patients who have not run this gauntlet. In cancer, as in many things, the earlier the intervention the better the prognosis.
Six months after receiving infusions of their own T cells - genetically engineere...
Source: Fight Aging! - March 3, 2017 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Johnson & Johnson Announces Plans to Disclose Average Price Increases
As America continues to discuss the increase in the cost of prescription drugs, Johnson & Johnson (J&J) has announced that it plans to disclose average price increases of its prescription drugs.
High and rising prices have also infuriated doctors, insurance companies and politicians, and triggered government probes into the industry's practices. The government has no power now to regulate prices, but the industry appears to be starting to move to deflect further scrutiny and avoid price controls.
With annual price tags topping $100,000 for many new drugs for cancer and rare diseases, some patients have been unable to...
Source: Policy and Medicine - March 2, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Reading The Fine Print: Do ACA Replacement Proposals Give States More Flexibility And Authority?
State officials have been heartened by statements from incoming Congressional leadership and the new President that states will gain greater authority and autonomy over their health insurance markets than they have had under the Affordable Care Act (ACA). For example, President Trump’s executive order on the ACA called for giving states “more flexibility and control to create a more free and open health care market.” Similarly, leading members of Congress have said, for example: “States, not the federal government, should have the primary responsibility for health policy,” and suggested that their replacement pla...
Source: Health Affairs Blog - February 23, 2017 Category: Health Management Authors: Sabrina Corlette and Kevin Lucia Tags: Following the ACA Insurance and Coverage interstate insurance States Source Type: blogs
